Hepatic encephalopathy (HE) is a major cause of morbidity in cirrhosis. However, its severity assessment is often subjective, which needs to be studied systematically. The aim was to determine how accurately trainee and nontrainee practitioners grade and manage HE patients throughout its severity. We performed a survey study using standardized simulated patient videos at 4 US and 3 Canadian centers. Participants were trainees (gastroenterology/hepatology fellows) and nontrainees (faculty, nurse practitioners, physician assistants). We determined the accuracy of HE severity identification and management options between grades <2 or 2 HE and trainees/nontrainees. In total, 108 respondents (62 trainees, 46 nontrainees) were included. For patients with grades <2 versus 2 HE, a higher percentage of respondents were better at correctly diagnosing grades 2 compared with grades <2 (91% versus 64%; P < 0.001). Specialized cognitive testing was checked significantly more often in grades <2, whereas more aggressive investigation for precipitating factors was ordered in HE grades >2. Serum ammonia levels were ordered in almost a third of grade 2 patients. For trainees and nontrainees, HE grades were identified similarly between groups. Trainees were less likely to order serum ammonia and lowprotein diets, more likely to order rifaximin, and more likely to perform a more thorough workup for precipitating factors compared with nontrainee respondents. There was excellent concordance in the classification of grade 2 HE between nontrainees versus trainees, but lower grades showed discordance. Important differences were seen regarding blood ammonia, specialized testing, and nutritional management between trainees and nontrainees. These results have important implications at the patient level, interpreting multicenter clinical trials, and in the education of practitioners.
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Cirrhosis and hepatic encephalopathy (HE) are major causes of morbidity and mortality in the United States, and the trend points toward a growing burden over time. (1) HE is defined as brain dysfunction caused by liver insufficiency and/or portosystemic shunting in the absence of other brain diseases, which manifests as a wide spectrum of neuropsychiatric abnormalities ranging from subclinical alterations to coma. (2) HE accounts for approximately 110,000 hospitalizations yearly (2005) (2006) (2007) (2008) (2009) and is the most common cause of readmission in decompensated patients with cirrhosis. (1, 3) Because of the complexity of this condition and its myriad presentations, most hospital-and clinicbased specialties such as emergency room, primary care, hospitalist medicine, critical care, and gastroenterology/hepatology specialists encounter these patients. (2) HE severity is viewed as a continuum but using the West Haven criteria is divided into grades 1-4 in patients exhibiting clinical signs of the disease (Table 1) . (4) The subclinical form, called minimal hepatic encephalopathy (MHE), cannot be diagnosed using the usual physical examination, and requires specialized cognitive testing. (3) However, the West Haven
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criteria can be subjective and semiquantitative, and their interobserver reliability needs to be studied. (4) (5) (6) The proper elucidation of HE grades is an important goal for teaching and research because management options vary greatly between different HE grades. In addition, several other questions in the management of HE, including the use of blood ammonia levels, restriction of protein, and use of appropriate medications and imaging remain controversial and centerspecific, but they have gained some clarity in recent guidelines. (2) Therefore, an analysis of the accurate diagnosis and subsequent management of HE across its spectrum of severity is a critical clinical, investigational, and educational goal.
The purpose of this study is to determine how accurately specialist trainee and nontrainee practitioners are able to properly grade and manage HE patients across grades of severity in order to evaluate consistency and management trends in the current practicing population.
Patients and Methods
The study was carried out between February and April 2017 as a quality improvement project. Participants in the study included US and Canadian trainee and nontrainee gastroenterology practitioners. Trainees included gastroenterology fellows along with internal medicine residents. Nontrainees included gastroenterology faculty members, nurse practitioners, and physician assistants. Each site was given freedom to plan how they performed the survey based on convenience and ability to get maximal participation. The study was described in detail and any participant who attended the sessions was allowed to leave if they did not wish to be involved. All gastrointestinal (GI) faculty and GI fellows were invited to participate in the study at each site, and the study was announced at the start of the conference. All participants were shown a series of standardized simulated patient videos during the same sitting as published in a prior study. (7) The videos demonstrated patients with cirrhosis with no HE (normal), and grades 1, 2, 3, and 4 HE using the West Haven criteria. Grades 2-4 occur in a simulated inpatient setting with a physician, the patient, and the patient's significant other. For the other 2 videos, normal and grade 1, the interactions took place in the outpatient setting in a physician's office with the physician, the patient, and his mother. The survey was developed under neuropsychological guidance (J.B.W., Supporting Information). The survey was paper-based, and after completion, it was manually collected and mailed or faxed to Virginia Commonwealth University for analysis. Section 1 of the survey tested grade identification. Section 2 of the survey assessed management and was divided into 5 domains (history-taking, initial management, course of action, investigations, and lastly therapies). Diagnostic and treatment appropriateness were based on the recommendations outlined in the 2014 American Association for the Study of Liver Diseases (AASLD)/European Association for the Study of the Liver (EASL) HE guidelines (2) (Supporting Table 1 ). The videos were shown in the same order (grade 4, grade 2, grade 3, normal, and finally grade 1) at all sites, and all respondents were asked to complete all questions in the survey after the completion of the video of 1 grade before moving to the next. Comparisons were performed in the identification and management of the grades, between grades 2 or higher compared with the lower ones, and also between trainees and nontrainee practitioners. Data analysis was This research was partly funded using VA merit review grant I0CX001076 and National Center for Advancing Translational Sciences National Institutes of Health R21TR002024 to Jasmohan S. Bajaj.
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performed via chi-square and Fisher's exact test using P < 0.05 for significance.
SAMPLE SIZE
Given the stability of the diagnosis of grade 2 or higher of HE, we assumed that 90% of respondents would be able to evaluate it compared with 60% of respondents in the lower HE grades. With a power of 90% and a of 0.05, we would require at least 42 respondents. Because we wanted to study trainees and nontrainees separately, our aim was to at least enroll 42 subjects in each group. This project was considered an educational, quality improvement project and was exempt from institutional review board approval at all institutions.
Results

DEMOGRAPHICS
There were slight variations from center to center in how the study was performed, but overall it was consistent. Selected GI faculty and GI fellows at each site, who were trained by J.S.B. and B.R., ran the survey sessions. All sessions were combined and included both trainees and nontrainees. The people who invited the participants were the same ones to play the videos and administer the survey within the same session. The study was performed during a regularly scheduled conference time (grand rounds, noon conferences, and didactics sessions). The response rate was 100% for all conference attendees (trainee and nontrainee) at all sites. In total, there were 108 respondents (62 trainees, 46 nontrainees) from 7 centers (77 from 4 US centers and 31 from 3 Canadian centers). Trainees included 18 first year, 16 second year, 12 third year, 14 fourth year hepatology fellows, and 2 internal medicine residents. Nontrainees included 41 gastroenterology consultants and 5 midlevel practitioners.
GRADE IDENTIFICATION
A higher percentage of total respondents correctly diagnosed grades 2 compared with grades <2 (Fig. 1) . HE grades were identified similarly between trainees and nontrainees ( Table 2 ). The breakdown between respondents across groups is shown in Supporting Table 2 .
COMPARISON BETWEEN GRADES 2 AND <2 IN ALL RESPONDENTS
As shown in Table 3 , most respondents would inquire about patient stool number and medication history for all grades, whereas most participants would perform a neurological examination for focal deficits only in grades 2. On the other hand, specialized MHE testing was checked significantly more often in HE grades <2. In the workup, blood tests to define potential precipitating factors and other causes of altered mental status were ordered in the majority of grade 2 patients. Serum ammonia levels would be ordered in almost a third of grade 2 patients, higher than the lower grades. HE-specific therapies (lactulose and rifaximin), intravenous albumin and antibiotics, and brain imaging were more commonly ordered for grade 2 patients. Patients with more advanced HE were also more likely to receive nutritional consults. Lowprotein diets were ordered at a similar low rate across all HE grades.
TRAINEE VERSUS NONTRAINEE MANAGEMENT
When management was compared between trainee and nontrainee respondents, we found a statistically similar response to most questions except a few important ones (Table 4) . Specifically, trainees were more likely to do the following:
1. Inquire about bowel movement frequency irrelevant of the severity of HE. 
Discussion
The current study results show that an accurate and reproducible assessment of lower grades of HE remains problematic even among trainees and practitioners of the subspecialty of gastroenterology. The results also demonstrate that trainees and practitioners had significant differences in the management of HE grades primarily in investigations, nutrition, and medical therapies. These results have important implications with respect to patient care, resource utilization, conduct of multicenter clinical trials, and most importantly in the training and continuing education of practitioners who deal with this complex patient population. The lack of reproducibility in the diagnosis of the lower HE stages is not unexpected given the semiquantitative nature of the "gold standard," the West Haven criteria for HE. Given these uncertainties, regulatory agencies such as the Food and Drug Administration have mandated use of other instruments to gauge severity of HE, especially for the earlier grades for future clinical trials. (7) Also in response to this difficulty, the recent international guidelines for HE have combined grade 1 HE and MHE into covert hepatic encephalopathy (CHE). (2, 8) This study highlights the utility of this approach in the guidelines because there is a major gap in differentiating between "normal" and grade 1 HE, whereas there is excellent agreement between grades 2, 3, and 4.
The inability to accurately identify HE grades <2 could potentially result in inappropriate management of this patient population and affect multicenter clinical research. This is particularly important in trials in which grade 1 HE is a major endpoint. This lack of agreement in the specialist community (both trainees and nontrainee practitioners) does not bode well for the adequate resolution of this situation. In most practices, grade 1 HE is diagnosed clinically through the experience of the investigator or in most cases on inquiry with the companions of the patients. However, this is highly dependent on the presence of the companion, familiarity of the patient to the clinician, as well as availability of time that is required for the practitioner to ask these questions. A recent study to better define grade 1 using the simple animal naming test has been published, which requires further validation in other centers to study its ability to define this grade.
The deficiency in this knowledge was also highlighted by the relatively few respondents who ordered specialized testing for MHE to better define lower grades of HE. These tests, which range from simple applicationbased tests to sophisticated neuropsychological tools, can be important in prognosticating overt hepatic encephalopathy (OHE) development, indicating poor quality of life, and helping educate patients and caregivers about HE. (2, 10, 11) In cases such as these where the identification of "normal" and grade 1 is in doubt, MHE testing results could add an important component to the decision-making process and is recommended for every at-risk patient with cirrhosis per guidelines. (2) Given the stability of the diagnosis beyond grade 2, the definition of all other grades below that as CHE seems to be an important option until better operative criteria are defined for grade 1 in multicenter studies. Efforts must be made to improve training in this area at every level including during medical school, residency, and fellowship. Online learning tutorials, phone applications, and standardized curricula are all possible supplemental options for improving trainee and nontrainee knowledge in this area. Specific standardized patients to simulate inpatient and outpatient visits may be necessary tools for this complex population as well.
This study also provides evidence of knowledge deficiencies in the proper management of this patient population including improper understanding of MHE testing, precipitant evaluations, diet/nutritional needs, and treatment options. The appropriateness was judged based on the 2014 HE AASLD/EASL guideline recommendations. The burden of HE and chronic liver disease will continue to grow, and proper management is key for improving patient survival, reducing hospital cost/readmission rates, and maximizing reimbursement. In 2003, patients hospitalized with HE generated charges of approximately US $1 billion, and this cost will continue to rise in coming years. (1, 12) Under-staging could lead to an incomplete workup of precipitating factors, delay in escalation of care, and ineffective treatment strategies, whereas the reverse could lead to resource mismanagement with increased costs and a higher patient exposure to medications, expensive imaging studies, and invasive procedures.
Most HE episodes have a precipitating factor, the identification and correction of which is essential for the improvement of symptoms. (2, 13, 14) For HE grades 2, there was an adequate workup of these factors for most practitioners, although specific issues were identified. Although the latest guidelines do not advise it, nontrainee practitioners had a higher rate of inappropriate ammonia level ordering across all HE grades despite evidence that high blood ammonia levels alone do not add any diagnostic, staging, or prognostic value. (2) There is a strong consensus that low-protein diets should be avoided in HE patients. (15, 16) Unfortunately, almost 10% of participants continued to order low-protein diets in all HE grades instead of ordering robust nutritional assessments for patients. This highlights nutrition as an area of concern. Another response element group that was concerning was the relatively high proportion of respondents who would perform brain scanning with computed tomography or magnetic resonance imaging in patients with advanced HE grades, which although useful to detect intracerebral hemorrhage, has been shown to be of doubtful value in patients without focal neurological deficits. (17, 18) Currently only OHE is routinely treated. Although most practitioners ordered lactulose correctly for OHE patients, they also treated patients with grades <2 over half the time leading to concerns for overtreatment in this patient population. Rifaximin alternatively was ordered less frequently for OHE patients by nontrainees. This could be logistically challenging in Canada, where rifaximin has only recently become easier to access. However, in patients who are intolerant of lactulose, there is a good evidence basis for the use of rifaximin. (19) When comparing trainees to nontrainees, the general trend emerged that trainees were more aggressive in their workup and management of OHE patients, whereas nontrainees were more thorough in their workup of HE patients grade <2. Maintaining currency on newer guideline changes is critical in providing standard of care treatment. The responses of nontrainees showed that they were more likely to order ammonia levels and low-protein diets, whereas showing hesitancy prescribing rifaximin demonstrates these differences. Therefore, there remains a need for continued re-education of the practitioner population regarding guideline changes during continuing medical education.
Although this study identified a major inconsistency in diagnosing HE, it also had limitations including practitioner sample size and the number of included GI programs in the United States and Canada. Participants were obliged to make staging decisions and management options based on another physician's interview, which may not have included all or some of the questions the participant would ask in their clinical practice. Because of the structure of the study, some participants may have thought that a "normal" patient was not included as part of the videos even though this was listed as a possible staging selection choice. Ideally, it would have been beneficial to expand the detail of certain management topics. For example, MHE testing could have been split into the many different possible tests available, but due to an overall lack of consensus in this field, relatively finer details of MHE testing were not included. We also determined that anonymity regarding center location would aid in a more transparent educational experience; therefore, individual center data could not be compared. In most centers, both trainees and nontrainees completed the survey in the same room, which could encourage for possible contamination of responses. We only limited ourselves to GI practitioners and trainees given a higher likelihood of encountering HE patients routinely, but further research into understanding HE needs to be expanded to other medicine residents, hospitalists, and emergency room and critical care specialties.
We conclude that in this multicenter international survey using simulated standardized patients, there was excellent concordance between stage 2 or higher for HE, whereas lower stages showed significant discordance. There were also important differences found regarding blood ammonia levels, specialized cognitive testing, and nutritional management between trainees and nontrainee practitioners. Further research in this area should be directed at operationalizing the grading of earlier HE grades, and improving education of trainees and nontrainee practitioners regarding the current treatment guidelines to improve patient care. This could have an important impact on resource utilization, clinical research, and education.
